Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. China Regenerative Medicine International's
Operating Income
for the
six
months ended in Dec. 2025 was HK$1.48 Mil. China Regenerative Medicine International's Interest Expense for the
six
months ended in Dec. 2025 was HK$-0.55 Mil.
China Regenerative Medicine International's interest coverage for the quarter that ended in Dec. 2025 was 2.71.
The higher the ratio, the stronger the company's financial strength is.
HKSE:08158's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07 * Ranked among companies with meaningful Interest Coverage only.
China Regenerative Medicine International (HKSE:08158) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
China Regenerative Medicine International Interest Coverage Related Terms
China Regenerative Medicine International Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
China Regenerative Medicine International Interest Coverage Chart
China Regenerative Medicine International Annual Data
HKSE:08158 vs VRTX, REGN, RVMD: Interest Coverage Comparison
For the Biotechnology subindustry, China Regenerative Medicine International's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Regenerative Medicine International Interest Coverage vs Biotechnology Industry
China Regenerative Medicine International Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International (HKSE:08158) has a Interest Coverage of 2.71 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on China Regenerative Medicine International and its competitors. This is 83% below median its historical median of 16.31. According to the industry distribution chart, China Regenerative Medicine International ranks #999999 out of 373 companies in the Biotechnology industry.
Is China Regenerative Medicine International's Interest Coverage too high?
China Regenerative Medicine International's current Interest Coverage of 2.71 is 83% below median its 10-year median of 16.31. The Biotechnology industry median Interest Coverage is 106.07. China Regenerative Medicine International's value of 2.71 is 97.4% below this industry median. Based on the distribution chart, China Regenerative Medicine International ranks #999999 out of 373 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, China Regenerative Medicine International has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China Regenerative Medicine International's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, China Regenerative Medicine International ranks #999999 out of 373 companies for Interest Coverage. This places China Regenerative Medicine International in the lower half of its industry. The industry median Interest Coverage is 106.07. China Regenerative Medicine International's value of 2.71 is 97.4% below this benchmark. While the company's 10-year median is 16.31 vs. the industry median of 106.07, China Regenerative Medicine International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 373 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Regenerative Medicine International's current Interest Coverage of 2.71 is 97.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on China Regenerative Medicine International and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Regenerative Medicine International's current Interest Coverage is 2.71, which is 83% below median its own 10-year median of 16.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Regenerative Medicine International stock overvalued right now?
Based on GuruFocus' analysis, China Regenerative Medicine International (HKSE:08158) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.63, compared to a current price of HK$0.23 — trading 63.2% below its estimated fair value. The current Interest Coverage is 2.71, which is 83% below median its 10-year median of 16.31 and 97.4% below the Biotechnology industry median of 106.07. China Regenerative Medicine International's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For China Regenerative Medicine International (HKSE:08158), the current Interest Coverage is 2.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Regenerative Medicine International (HKSE:08158) Overvalued in 2026?
Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued.
The current stock price of HK$0.23 is trading 63.2% below its estimated GF Value™ of HK$0.63.
GuruFocus considers China Regenerative Medicine International to be Possible Value Trap.
Key valuation signals for HKSE:08158:
Interest Coverage: 2.71 (83% below median its 10-year median of 16.31)
GF Value™: HK$0.63 vs. price of HK$0.23 (63.2% below fair value)
Industry Position: 97.4% below the Biotechnology median (#999999 of 373)
No single metric tells the full story. See the HKSE:08158 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score
Get the complete analysis for HKSE:08158
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08158 has been successfully added to your 
